

CREAD

An Alzheimer's Disease Study

Aim

To evaluate the effect of the monoclonal antibody RO5490245 – crenezumab (administered by monthly infusions) – in slowing cognitive decline in subjects with prodromal to mild Alzheimer's disease (AD).

Phase III

A two-year multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of crenezumab in participants with prodromal to mild AD.

Hypothesis

Crenezumab binds to A β oligomers to delay AD progression.

Ethics approval

Bellberry Human Research Ethics Committee 2015-12-848.

Trial NCT02670083

Funding

- F. Hoffmann-La Roche Ltd
- Neurodegenerative Disorders Research Pty Ltd

Criteria

To be eligible for the CREAD Study participants must:

- be aged between 50-85 years,
- have prodromal to mild AD,
- have increased brain amyloid, and
- have a mini mental state examination score of ≥ 22 .

Status

Currently enrolling

Principal Investigator

Professor Peter K Panegyres, MD PhD FRACP
Principal Investigator
Neurodegenerative Disorders Research Pty Ltd
4 Lawrence Avenue, West Perth WA 6005

Phone: (08) 9481 6293
Fax: (08) 9481 6294

Email: clinicaltrials@ndr.org.au